• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗老年糖尿病患者:特殊考虑因素。

Treating the elderly diabetic patient: special considerations.

机构信息

Department of Internal Medicine F, Soroka University Medical Center, Beer-Sheva, Israel.

出版信息

Diabetes Metab Syndr Obes. 2014 Aug 28;7:391-400. doi: 10.2147/DMSO.S48898. eCollection 2014.

DOI:10.2147/DMSO.S48898
PMID:25210468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4154881/
Abstract

The prevalence of diabetes is rising in the >65 year-old group. The challenge of defining the goals of therapy arises from the heterogeneity of the aging process and the sparse clinical data in this patient population. In light of these challenges, the clinician should be aware of the pitfalls of caring for the older diabetic patient and prioritize an individualized treatment plan to ensure an optimal glycemic control, without placing the patient at unnecessary risk. We present a review of the current guidelines and literature that deal specifically with the treatment of the older diabetic patient in order to establish the principles of treatment in this age group and help the clinician make decisions regarding the care of these patients.

摘要

65 岁人群中糖尿病的患病率正在上升。由于衰老过程的异质性和该患者人群中临床数据的缺乏,定义治疗目标的挑战随之而来。有鉴于此,临床医生应该意识到照顾老年糖尿病患者的陷阱,并优先制定个性化的治疗计划,以确保血糖得到最佳控制,而不会使患者面临不必要的风险。我们回顾了目前专门针对老年糖尿病患者治疗的指南和文献,以确定该年龄组的治疗原则,并帮助临床医生做出关于这些患者护理的决策。

相似文献

1
Treating the elderly diabetic patient: special considerations.治疗老年糖尿病患者:特殊考虑因素。
Diabetes Metab Syndr Obes. 2014 Aug 28;7:391-400. doi: 10.2147/DMSO.S48898. eCollection 2014.
2
Optimal therapy of type 2 diabetes: a controversial challenge.2型糖尿病的最佳治疗:一项具有争议性的挑战。
Aging (Albany NY). 2014 Mar;6(3):187-206. doi: 10.18632/aging.100646.
3
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响:患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
4
Treating diabetes mellitus in older and oldest old patients.治疗老年及高龄患者的糖尿病
Curr Pharm Des. 2015;21(13):1665-71. doi: 10.2174/1381612821666150130120747.
5
Behavioural interventions for type 2 diabetes: an evidence-based analysis.2型糖尿病的行为干预:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(21):1-45. Epub 2009 Oct 1.
6
Insulin use in elderly diabetic patients.老年糖尿病患者胰岛素的使用
Clin Interv Aging. 2006;1(2):107-13. doi: 10.2147/ciia.2006.1.2.107.
7
Care of elderly patients with diabetes mellitus: a focus on frailty.老年 2 型糖尿病患者的护理:关注虚弱。
Ageing Res Rev. 2010 Nov;9 Suppl 1:S18-22. doi: 10.1016/j.arr.2010.08.008. Epub 2010 Sep 19.
8
Individualized HbA Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey.个体化 HbA1c 目标与 2 型糖尿病患者的知晓和达标情况:一项真实世界的跨国调查。
Adv Ther. 2022 Feb;39(2):1016-1032. doi: 10.1007/s12325-021-01985-3. Epub 2021 Dec 24.
9
10
Management of type 2 diabetes mellitus in older patients: current and emerging treatment options.老年 2 型糖尿病患者的管理:现有和新兴的治疗选择。
Diabetes Ther. 2013 Dec;4(2):239-56. doi: 10.1007/s13300-013-0039-6. Epub 2013 Oct 5.

引用本文的文献

1
Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.衰老对老年患者长期用药药效学和药代动力学的影响:综述
Clin Pharmacokinet. 2025 Mar;64(3):335-367. doi: 10.1007/s40262-024-01466-0. Epub 2025 Jan 11.
2
Potentially Inappropriate Use of Medication and Its Determinants Among Ambulatory Older Adults in Six Community Chain Pharmacies in Asmara, Eritrea: A Cross-Sectional Study Using the 2023 American Geriatric Society Beers Criteria.在厄立特里亚阿斯马拉的六家社区连锁药店中,使用 2023 年美国老年医学会 Beers 标准对门诊老年患者进行潜在不适当药物使用及其决定因素的横断面研究。
Clin Interv Aging. 2024 Jul 1;19:1177-1187. doi: 10.2147/CIA.S466649. eCollection 2024.
3
The Age-Dependent Increase of Metabolic Syndrome Requires More Extensive and Aggressive Non-Pharmacological and Pharmacological Interventions: A Cross-Sectional Study in an Italian Cohort of Obese Women.代谢综合征随年龄增长而增加,需要更广泛、更积极的非药物和药物干预:一项针对意大利肥胖女性队列的横断面研究。
Int J Endocrinol. 2021 Apr 23;2021:5576286. doi: 10.1155/2021/5576286. eCollection 2021.
4
Current situation analysis of diabetic home care patients.糖尿病居家护理患者的现状分析
North Clin Istanb. 2019 Oct 25;7(2):140-145. doi: 10.14744/nci.2019.59751. eCollection 2020.
5
HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.HbA1c 目标达标情况:在口服抗糖尿病药物控制不佳的 2 型糖尿病患者中起始使用甘精胰岛素 100 U/mL 滴定和优化试验的结果。
BMJ Open Diabetes Res Care. 2019 Aug 1;7(1):e000668. doi: 10.1136/bmjdrc-2019-000668. eCollection 2019.
6
Breaking Therapeutic Inertia in Type 2 Diabetes: Active Detection of In-Patient Cases Allows Improvement of Metabolic Control at Midterm.打破2型糖尿病治疗惰性:主动筛查住院病例可在中期改善代谢控制。
Int J Endocrinol. 2015;2015:381415. doi: 10.1155/2015/381415. Epub 2015 May 18.

本文引用的文献

1
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病:系统评价和荟萃分析。
Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007.
2
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.沙格列汀与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.
3
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.在二甲双胍控制不佳的 2 型糖尿病患者中,卡格列净对比格列美脲的疗效和安全性(CANTATA-SU):一项随机、双盲、3 期非劣效性临床试验的 52 周结果。
Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.
4
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.2型糖尿病患者的磺脲类单药治疗
Cochrane Database Syst Rev. 2013 Apr 30(4):CD009008. doi: 10.1002/14651858.CD009008.pub2.
5
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.卡格列净对比西格列汀治疗二甲双胍联合磺脲类药物血糖控制不佳的 2 型糖尿病患者:一项 52 周随机试验。
Diabetes Care. 2013 Sep;36(9):2508-15. doi: 10.2337/dc12-2491. Epub 2013 Apr 5.
6
Standards of medical care in diabetes--2013.《糖尿病医疗护理标准——2013》
Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S11-66. doi: 10.2337/dc13-S011.
7
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.度拉糖肽每周 1 次与艾塞那肽每周 1 次治疗 2 型糖尿病患者的疗效比较(DURATION-6):一项随机、开放标签研究。
Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.
8
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.磺酰脲类药物和二甲双胍单药治疗 2 型糖尿病患者心血管事件的效果比较:一项队列研究。
Ann Intern Med. 2012 Nov 6;157(9):601-10. doi: 10.7326/0003-4819-157-9-201211060-00003.
9
Diabetes in older adults: a consensus report.老年糖尿病:一份共识报告。
J Am Geriatr Soc. 2012 Dec;60(12):2342-56. doi: 10.1111/jgs.12035. Epub 2012 Oct 25.
10
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.SGLT2 受体抑制剂在 2 型糖尿病双联或三联疗法中的系统评价。
BMJ Open. 2012 Oct 18;2(5). doi: 10.1136/bmjopen-2012-001007. Print 2012.